ARK Investment Management, led by founder and chief executive Cathie Wood, has accumulated shares of Arcturus Therapeutics Holdings across various actively managed healthcare and innovation exchange-traded funds. These investment allocations align with her firm's long-term strategy of funding disruptive biotechnology platforms, genomics research, and cutting-edge messenger RNA medicine delivery systems.